Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

0.8001 -0.0099 (-1.22%)
Streaming Delayed Price Updated: 2:53 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision Biosciences Inc

< Previous 1 2 3 4 5 6 Next >
Precision BioSciences to Present at Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
From Precision BioSciences, Inc.
Via Business Wire
Preview: Precision BioSciences's Earnings
 
Via Benzinga
Looking Into Precision BioSciences's Return On Capital Employed
 
Via Benzinga
Preview: Precision BioSciences's Earnings
 
Via Benzinga
Precision BioSciences Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
From Precision BioSciences, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
 
Via Benzinga
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
From Precision BioSciences
Via Business Wire
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.